Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy

被引:98
作者
Li, Xiao-Feng [1 ]
Carlin, Sean [1 ]
Urano, Muneyasu [1 ]
Russell, James [1 ]
Ling, C. Clifton [1 ]
O'Donoghue, Joseph A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA
关键词
D O I
10.1158/0008-5472.CAN-06-4353
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor hypoxia is commonly observed in primary solid malignancies but the hypoxic status of subclinical micro-metastatic disease is largely unknown. The distribution of hypoxia in microscopic tumors was studied in animal models of disseminated peritoneal disease and intradermal (i.d.) growing tumors. Tumors derived from human colorectal adenocarcinoma cell lines HT29 and HCT-8 ranged in size from a few hundred microns to several millimeters in diameter. Hypoxia was detected by immunofluorescent visualization of pimonidazole and the hypoxia-regulated protein carbonic anhydrase 9. Tumor blood perfusion, cellular proliferation, and vascularity were visualized using Hoechst 33342, bromodeoxyuridine, and CD31 staining, respectively. In general, tumors of <1 mm diameter were intensely hypoxic, poorly perfused, and possessed little to no vasculature. Larger tumors (similar to 1-4 mm diameter) were well perfused with widespread vasculature and were not significantly hypoxic. Patterns of hypoxia in disseminated peritoneal tumors and i.d. tumors were similar. Levels of hypoxia in microscopic peritoneal tumors were reduced by carbogen breathing. Peritoneal and i.d. tumor models are suitable for studying hypoxia in microscopic tumors. If the patterns of tumor hypoxia in human patients are similar to those observed in these animal experiments, then the efficacy of systemic treatments of micrometastatic disease may be compromised by hypoxic resistance.
引用
收藏
页码:7646 / 7653
页数:8
相关论文
共 41 条
[21]   Investigational agents for epithelial ovarian cancer [J].
Muggia, Franco ;
Kosloff, Rebecca .
EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) :855-868
[22]   Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck [J].
Nordsmark, M ;
Overgaard, M ;
Overgaard, J .
RADIOTHERAPY AND ONCOLOGY, 1996, 41 (01) :31-39
[23]   Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial [J].
Overgaard, J ;
Eriksen, JG ;
Nordsmark, M ;
Alsner, J ;
Horsman, MR .
LANCET ONCOLOGY, 2005, 6 (10) :757-764
[24]   Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer [J].
Potter, CPS ;
Harris, AL .
BRITISH JOURNAL OF CANCER, 2003, 89 (01) :2-7
[25]   Regulation of angiogenesis by hypoxia: role of the HIF system [J].
Pugh, CW ;
Ratcliffe, PJ .
NATURE MEDICINE, 2003, 9 (06) :677-684
[26]   Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors [J].
Raleigh, JA ;
Chou, SC ;
Arteel, GE ;
Horsman, MR .
RADIATION RESEARCH, 1999, 151 (05) :580-589
[27]  
Raleigh JA, 1998, CANCER RES, V58, P3765
[28]  
Schneider RF, 1997, J LABELLED COMPD RAD, V39, P541, DOI 10.1002/(SICI)1099-1344(199707)39:7<541::AID-JLCR5>3.0.CO
[29]  
2-B
[30]   Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies [J].
Shannon, AM ;
Bouchier-Hayes, DJ ;
Condron, CM ;
Toomey, D .
CANCER TREATMENT REVIEWS, 2003, 29 (04) :297-307